Citigroup
CNTX icon

Citigroup’s Context Therapeutics CNTX Stock Holding History

Citigroup’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$31.9K Buy
12,182
+10,834
+804% +$25.3K ﹤0.01% 4681
2025
Q4 		$1.98K Buy
+1,348
New +$1.57K ﹤0.01% 5457
2025
Q1 		– Sell
-54,454
Closed -$57.2K – 5652
2024
Q4 		$57.2K Buy
54,454
+9,675
+22% +$16.7K ﹤0.01% 5053
2024
Q3 		$87.8K Buy
+44,779
New +$99.3K ﹤0.01% 4816

Other funds holding CNTX

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Citigroup's CNTX Position: Q1 2026 in Review

Citigroup increased its Context Therapeutics (CNTX) stake by 804% in Q1 2026, buying an estimated $25.3K and bringing the position to 12,182 shares worth $31.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4681.

Citigroup first reported a position in CNTX in Q3 2024 and has held it in 4 quarters since. The position peaked at $87.8K in Q3 2024. 59 funds tracked by Wall St. Rank hold CNTX as of Q1 2026.

  • Citigroup held 12,182 shares of Context Therapeutics worth $31.9K as of Q1 2026.
  • Citigroup bought 10,834 Context Therapeutics shares in Q1 2026, an estimated $25.3K.
  • Context Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4681 holding.
  • Citigroup first reported a position in Context Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • Citigroup's Context Therapeutics position peaked at $87.8K in Q3 2024.
  • 59 funds tracked by Wall St. Rank held Context Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.